Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2019

December 2019 | 58 pages | ID: VAFB03C7DA6EN
Global Markets Direct

Abstracts

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2019, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline landscape.

Vancomycin resistant staphylococcus infection is a condition caused by bacteria (germs). This infection occurs when bacteria, called Staphylococcus aureus or Staph, becomes resistant (not killed) to the antibiotic medicine vancomycin. Risk factors include taking strong antibiotics the wrong way may cause the bacteria to develop resistance to the antibiotics, weak immune system and staying in the hospital too long. Symptoms include fever, chills, cough, chest pain, trouble breathing, and a fast heartbeat.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Overview
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Companies Involved in Therapeutics Development
21st Century Therapeutics Inc
Amprologix Ltd
CrystalGenomics Inc
Debiopharm International SA
Destiny Pharma Plc
Lysimmune BioScience
Roivant Sciences Ltd
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
Wockhardt Ltd
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drug Profiles
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by 21st Century Therapeutics Inc, H2 2019
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Amprologix Ltd, H2 2019
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by CrystalGenomics Inc, H2 2019
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Debiopharm International SA, H2 2019
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Destiny Pharma Plc, H2 2019
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Lysimmune BioScience, H2 2019
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Roivant Sciences Ltd, H2 2019
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by TGV-Inhalonix Inc, H2 2019
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, H2 2019
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Wockhardt Ltd, H2 2019
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects, H2 2019
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019